Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections

Sara Terreri; Eva Piano Mortari; Maria Rosaria Vinci; Cristina Russo; Claudia Alteri; Christian Albano; Francesca Colavita; Giulia Gramigna; Chiara Agrati; Giulia Linardos; Luana Coltella; Luna Colagrossi; Gloria Deriu; Marta Ciofi Degli Atti; Caterina Rizzo; Marco Scarsella; Rita Brugaletta; Vincenzo Camisa; Annapaola Santoro; Giuseppe Roscilli; Emiliano Pavoni; Alessia Muzi; Nicola Magnavita; Rossana Scutari; Alberto Villani; Andrea Villani; Massimiliano Raponi; Federica Locatelli; Carlo Federico Perno; Salvatore Zaffina; Rita Carsetti

doi:10.1016/j.chom.2022.01.003

Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections

Sara Terreri, Eva Piano Mortari, Maria Rosaria Vinci, Cristina Russo, Claudia Alteri, Christian Albano, Francesca Colavita, Giulia Gramigna, Chiara Agrati, Giulia Linardos, Luana Coltella, Luna Colagrossi, Gloria Deriu, Marta Ciofi Degli Atti, Caterina Rizzo, Marco Scarsella, Rita Brugaletta, Vincenzo Camisa, Annapaola Santoro, Giuseppe RoscilliEmiliano Pavoni, Alessia Muzi, Nicola Magnavita, Rossana Scutari, Alberto Villani, Andrea Villani, Massimiliano Raponi, Federica Locatelli, Carlo Federico Perno, Salvatore Zaffina, Rita Carsetti

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

Abstract

Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a consequence of waning immunity. Serum antibodies represent the most measurable outcome of vaccine-induced B cell memory. When antibodies decline, memory B cells are expected to persist and perform their function, preventing clinical disease. We investigated whether BNT162b2 mRNA vaccine induces durable and functional B cell memory in vivo against SARS-CoV-2 3, 6, and 9 months after the second dose in a cohort of health care workers (HCWs). While we observed physiological decline of SARS-CoV-2-specific antibodies, memory B cells persist and increase until 9 months after immunization. HCWs with breakthrough infections had no signs of waning immunity. In 3–4 days, memory B cells responded to SARS-CoV-2 infection by producing high levels of specific antibodies in the serum and anti-Spike IgA in the saliva. Antibodies to the viral nucleoprotein were produced with the slow kinetics typical of the response to a novel antigen.

Lingua originale	English
pagine (da-a)	400-408
Numero di pagine	9
Rivista	CELL HOST & MICROBE
DOI	https://doi.org/10.1016/j.chom.2022.01.003
Stato di pubblicazione	Pubblicato - 2022

Keywords

COVID-19
SARS-CoV-2
breakthrough infections
mRNA vaccine
memory B cells
mucosal immunity
salivary IgA
waning immunity

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.chom.2022.01.003

Altri file e collegamenti

Open Access link a IRIS PubliCatt

Cita questo

Terreri, S., Piano Mortari, E., Vinci, M. R., Russo, C., Alteri, C., Albano, C., Colavita, F., Gramigna, G., Agrati, C., Linardos, G., Coltella, L., Colagrossi, L., Deriu, G., Ciofi Degli Atti, M., Rizzo, C., Scarsella, M., Brugaletta, R., Camisa, V., Santoro, A., ... Carsetti, R. (2022). Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. CELL HOST & MICROBE, 400-408. https://doi.org/10.1016/j.chom.2022.01.003

@article{d36dc0fe984044e39cb307d573e442bc,

title = "Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections",

abstract = "Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a consequence of waning immunity. Serum antibodies represent the most measurable outcome of vaccine-induced B cell memory. When antibodies decline, memory B cells are expected to persist and perform their function, preventing clinical disease. We investigated whether BNT162b2 mRNA vaccine induces durable and functional B cell memory in vivo against SARS-CoV-2 3, 6, and 9 months after the second dose in a cohort of health care workers (HCWs). While we observed physiological decline of SARS-CoV-2-specific antibodies, memory B cells persist and increase until 9 months after immunization. HCWs with breakthrough infections had no signs of waning immunity. In 3–4 days, memory B cells responded to SARS-CoV-2 infection by producing high levels of specific antibodies in the serum and anti-Spike IgA in the saliva. Antibodies to the viral nucleoprotein were produced with the slow kinetics typical of the response to a novel antigen.",

keywords = "COVID-19, SARS-CoV-2, breakthrough infections, mRNA vaccine, memory B cells, mucosal immunity, salivary IgA, waning immunity, COVID-19, SARS-CoV-2, breakthrough infections, mRNA vaccine, memory B cells, mucosal immunity, salivary IgA, waning immunity",

author = "Sara Terreri and {Piano Mortari}, Eva and Vinci, {Maria Rosaria} and Cristina Russo and Claudia Alteri and Christian Albano and Francesca Colavita and Giulia Gramigna and Chiara Agrati and Giulia Linardos and Luana Coltella and Luna Colagrossi and Gloria Deriu and {Ciofi Degli Atti}, Marta and Caterina Rizzo and Marco Scarsella and Rita Brugaletta and Vincenzo Camisa and Annapaola Santoro and Giuseppe Roscilli and Emiliano Pavoni and Alessia Muzi and Nicola Magnavita and Rossana Scutari and Alberto Villani and Andrea Villani and Massimiliano Raponi and Federica Locatelli and Perno, {Carlo Federico} and Salvatore Zaffina and Rita Carsetti",

year = "2022",

doi = "10.1016/j.chom.2022.01.003",

language = "English",

pages = "400--408",

journal = "CELL HOST & MICROBE",

issn = "1931-3128",

publisher = "Cambridge, MA : Cell Press",

}

Terreri, S, Piano Mortari, E, Vinci, MR, Russo, C, Alteri, C, Albano, C, Colavita, F, Gramigna, G, Agrati, C, Linardos, G, Coltella, L, Colagrossi, L, Deriu, G, Ciofi Degli Atti, M, Rizzo, C, Scarsella, M, Brugaletta, R, Camisa, V, Santoro, A, Roscilli, G, Pavoni, E, Muzi, A, Magnavita, N, Scutari, R, Villani, A, Villani, A, Raponi, M, Locatelli, F, Perno, CF, Zaffina, S & Carsetti, R 2022, 'Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections', CELL HOST & MICROBE, pagg. 400-408. https://doi.org/10.1016/j.chom.2022.01.003

TY - JOUR

T1 - Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections

AU - Terreri, Sara

AU - Piano Mortari, Eva

AU - Vinci, Maria Rosaria

AU - Russo, Cristina

AU - Alteri, Claudia

AU - Albano, Christian

AU - Colavita, Francesca

AU - Gramigna, Giulia

AU - Agrati, Chiara

AU - Linardos, Giulia

AU - Coltella, Luana

AU - Colagrossi, Luna

AU - Deriu, Gloria

AU - Ciofi Degli Atti, Marta

AU - Rizzo, Caterina

AU - Scarsella, Marco

AU - Brugaletta, Rita

AU - Camisa, Vincenzo

AU - Santoro, Annapaola

AU - Roscilli, Giuseppe

AU - Pavoni, Emiliano

AU - Muzi, Alessia

AU - Magnavita, Nicola

AU - Scutari, Rossana

AU - Villani, Alberto

AU - Villani, Andrea

AU - Raponi, Massimiliano

AU - Locatelli, Federica

AU - Perno, Carlo Federico

AU - Zaffina, Salvatore

AU - Carsetti, Rita

PY - 2022

Y1 - 2022

N2 - Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a consequence of waning immunity. Serum antibodies represent the most measurable outcome of vaccine-induced B cell memory. When antibodies decline, memory B cells are expected to persist and perform their function, preventing clinical disease. We investigated whether BNT162b2 mRNA vaccine induces durable and functional B cell memory in vivo against SARS-CoV-2 3, 6, and 9 months after the second dose in a cohort of health care workers (HCWs). While we observed physiological decline of SARS-CoV-2-specific antibodies, memory B cells persist and increase until 9 months after immunization. HCWs with breakthrough infections had no signs of waning immunity. In 3–4 days, memory B cells responded to SARS-CoV-2 infection by producing high levels of specific antibodies in the serum and anti-Spike IgA in the saliva. Antibodies to the viral nucleoprotein were produced with the slow kinetics typical of the response to a novel antigen.

AB - Breakthrough SARS-CoV-2 infections in fully vaccinated individuals are considered a consequence of waning immunity. Serum antibodies represent the most measurable outcome of vaccine-induced B cell memory. When antibodies decline, memory B cells are expected to persist and perform their function, preventing clinical disease. We investigated whether BNT162b2 mRNA vaccine induces durable and functional B cell memory in vivo against SARS-CoV-2 3, 6, and 9 months after the second dose in a cohort of health care workers (HCWs). While we observed physiological decline of SARS-CoV-2-specific antibodies, memory B cells persist and increase until 9 months after immunization. HCWs with breakthrough infections had no signs of waning immunity. In 3–4 days, memory B cells responded to SARS-CoV-2 infection by producing high levels of specific antibodies in the serum and anti-Spike IgA in the saliva. Antibodies to the viral nucleoprotein were produced with the slow kinetics typical of the response to a novel antigen.

KW - COVID-19

KW - SARS-CoV-2

KW - breakthrough infections

KW - mRNA vaccine

KW - memory B cells

KW - mucosal immunity

KW - salivary IgA

KW - waning immunity

KW - COVID-19

KW - SARS-CoV-2

KW - breakthrough infections

KW - mRNA vaccine

KW - memory B cells

KW - mucosal immunity

KW - salivary IgA

KW - waning immunity

UR - http://hdl.handle.net/10807/200146

U2 - 10.1016/j.chom.2022.01.003

DO - 10.1016/j.chom.2022.01.003

M3 - Article

SN - 1931-3128

SP - 400

EP - 408

JO - CELL HOST & MICROBE

JF - CELL HOST & MICROBE

ER -

Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo